Plasma Cell Neoplasms: MGUS and Myeloma

作者: A. Mahindra , T.W. Kelley

DOI: 10.1016/B978-0-12-386456-7.04109-5

关键词:

摘要: Neoplasms of plasma cells are a group diseases characterized by the presence clonal in bone marrow (BM). These entities placed into particular diagnostic category based on their overall clinical, laboratory, and pathological features. They range from relatively common, asymptomatic disorder called monoclonal gammopathy undetermined significance to progressive typically incurable disease multiple myeloma (MM). Neoplastic share many same morphological immunophenotypic features normal cells. also retain functions activities including production immunoglobulin (Ig) accumulation BM. However, cell neoplasms, derangement these leads typical signs symptoms disease. This includes cytopenias BM failure, lytic skeletal lesions due alterations microenvironment, Ig blood urine, and, related this, renal insufficiency glomerular deposition. Over last decade, there have been major advances treatment MM introduction whole new classes drugs such as proteasome inhibitors thalidomide-based immunomodulatory drugs. As such, patients now options, whereas formerly, transplant may only hope. There understanding underlying pathophysiology genetics, this has enabled better classification prognostication patients. article will review clinical features, criteria, with neoplasms.

参考文章(14)
Rafael Fonseca, Richard J. Bailey, Gregory J. Ahmann, S. Vincent Rajkumar, James D. Hoyer, John A. Lust, Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Gordon W. Dewald, Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood. ,vol. 100, pp. 1417- 1424 ,(2002) , 10.1182/BLOOD.V100.4.1417.H81602001417_1417_1424
A K Stewart, K Laumann, J B Allred, S J Mandrekar, S V Rajkumar, F Buadi, M Q Lacy, S R Hayman, M A Gertz, K D Short, A Dispenzieri, S Kumar, P R Greipp, J A Lust, S J Russell, D Dingli, S Zeldenrust, R Fonseca, P L Bergsagel, V Roy, J R Mikhael, Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) Leukemia. ,vol. 24, pp. 1934- 1939 ,(2010) , 10.1038/LEU.2010.190
Paul G. Richardson, Edie Weller, Sagar Lonial, Andrzej J. Jakubowiak, Sundar Jagannath, Noopur S. Raje, David E. Avigan, Wanling Xie, Irene M. Ghobrial, Robert L. Schlossman, Amitabha Mazumder, Nikhil C. Munshi, David H. Vesole, Robin Joyce, Jonathan L. Kaufman, Deborah Doss, Diane L. Warren, Laura E. Lunde, Sarah Kaster, Carol DeLaney, Teru Hideshima, Constantine S. Mitsiades, Robert Knight, Dixie-Lee Esseltine, Kenneth C. Anderson, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. ,vol. 116, pp. 679- 686 ,(2010) , 10.1182/BLOOD-2010-02-268862
P. Leif Bergsagel, W. Michael Kuehl, Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma Journal of Clinical Oncology. ,vol. 23, pp. 6333- 6338 ,(2005) , 10.1200/JCO.2005.05.021
Meletios A. Dimopoulos, Evangelos Terpos, Asher Chanan-Khan, Nelson Leung, Heinz Ludwig, Sundar Jagannath, Ruben Niesvizky, Sergio Giralt, Jean-Paul Fermand, Joan Bladé, Raymond L. Comenzo, Orhan Sezer, Antonio Palumbo, Jean-Luc Harousseau, Paul G. Richardson, Bart Barlogie, Kenneth C. Anderson, Pieter Sonneveld, Patrizia Tosi, Michele Cavo, S. Vincent Rajkumar, Brian G.M. Durie, Jésus San Miguel, Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group Journal of Clinical Oncology. ,vol. 28, pp. 4976- 4984 ,(2010) , 10.1200/JCO.2010.30.8791
Robert A Kyle, Terry M Therneau, S Vincent Rajkumar, Janice R Offord, Dirk R Larson, Matthew F Plevak, L Joseph Melton III, None, A long-term study of prognosis in monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. ,vol. 346, pp. 564- 569 ,(2002) , 10.1056/NEJMOA01133202
J S Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, M Beksac, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan, S V Rajkumar, B G M Durie, , J-L Harousseau, International uniform response criteria for multiple myeloma Leukemia. ,vol. 20, pp. 1467- 1473 ,(2006) , 10.1038/SJ.LEU.2404284
Ravi Vij, Michael Wang, Jonathan L. Kaufman, Sagar Lonial, Andrzej J. Jakubowiak, A. Keith Stewart, Vishal Kukreti, Sundar Jagannath, Kevin T. McDonagh, Melissa Alsina, Nizar J. Bahlis, Frederic J. Reu, Nashat Y. Gabrail, Andrew Belch, Jeffrey V. Matous, Peter Lee, Peter Rosen, Michael Sebag, David H. Vesole, Lori A. Kunkel, Sandra M. Wear, Alvin F. Wong, Robert Z. Orlowski, David S. Siegel, An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma Blood. ,vol. 119, pp. 5661- 5670 ,(2012) , 10.1182/BLOOD-2012-03-414359
A Palumbo, , S V Rajkumar, M A Dimopoulos, P G Richardson, J San Miguel, B Barlogie, J Harousseau, J A Zonder, M Cavo, M Zangari, M Attal, A Belch, S Knop, D Joshua, O Sezer, H Ludwig, D Vesole, J Bladé, R Kyle, J Westin, D Weber, S Bringhen, R Niesvizky, A Waage, M von Lilienfeld-Toal, S Lonial, G J Morgan, R Z Orlowski, K Shimizu, K C Anderson, M Boccadoro, B G Durie, P Sonneveld, M A Hussein, Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia. ,vol. 22, pp. 414- 423 ,(2008) , 10.1038/SJ.LEU.2405062